The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Esophagectomy

  • PATIENTS AND METHODS: One hundred fifty five patients with resectable esophageal cancer were randomly assigned to perioperative G-CSF at standard doses (77 patients) or placebo (76 patients), administered from 2 days before until day 7 after esophagectomy [1].
  • High-grade epithelial dysplasia is an indication for esophagectomy because of the prevalence of occult adenocarcinoma (43%) [2].
  • OBJECTIVE: The safe resection margin in esophagectomy for esophageal squamous cell carcinoma (SCC) was determined based on the extent of epithelial and subepithelial accessory lesions from the main lesions of esophageal SCC [3].
  • Dysphagia relief was similar in the CRT group vs. the CRT+E subgroup; however, a greater percentage of patients treated with chemoradiation alone had normal long-term swallowing function when compared to those patients also undergoing esophagectomy (100% vs. 73%) [4].
  • CONCLUSIONS: Brain metastases from carcinomas of the esophagus are relatively uncommon (3.6% in the esophagectomy cohort) [5].

Psychiatry related information on Esophagectomy


High impact information on Esophagectomy


Chemical compound and disease context of Esophagectomy

  • EXPERIMENTAL DESIGN: Fifty-two patients with resectable esophageal cancers (cT2-4, Nx, and M0) received neoadjuvant radiochemotherapy (cisplatin, 5-5-fluorouracil, 36 Gy) followed by transthoracic en bloc esophagectomy [11].
  • METHODS AND MATERIALS: Thirty-one patients with localized esophageal adenocarcinoma were enrolled in a Phase II study involving high dose radiation and concurrent 5-fluorouracil (5-FU)/mitomycin-C with or without esophagectomy [12].
  • METHODS: Reflux symptom evaluation, endoscopy, and simultaneous 24-h pH and bilirubin monitoring in the cervical esophagus were performed in 25 patients who underwent Ivor Lewis esophagectomy, intrathoracic esophagogastrostomy, and digital dilation of the pyloric ring as treatment for esophageal cancer [13].
  • SETTING: Yamaguchi University School of Medicine, Kogushi, Japan. PATIENTS: A random sample of 21 patients selected from 79 patients with esophageal cancer during the period from May 1988 to August 1993 received the intrathoracic stomach after subtotal esophagectomy [14].
  • Sections of formalin-fixed and paraffin-embedded tissue from 31 esophagectomy specimens were immunostained for ER-B using the immunoperoxidase technique, and the percent of positive cells in areas of Barrett's metaplasia negative for dysplasia (ND), low-grade dysplasia (LGD), high-grade dysplasia (HGD) and adecocarcinoma, (CA) were recorded [15].

Biological context of Esophagectomy


Anatomical context of Esophagectomy


Associations of Esophagectomy with chemical compounds

  • METHODS: Thirty-two patients underwent manometry, simultaneous 24-hour pH and bilirubin monitoring, and endoscopy with biopsy 3 to 10.4 years after esophagectomy [26].
  • Sixteen patients undergoing total esophagectomy were evenly randomized and received TPN without or with L-carnitine supplementation (74 during 11 postoperative days [27].
  • As neoadjuvant CT, cisplatin of 50 mg/body/week was administered 2-5 times (100-250 mg in total) until 7-10 days before subtotal esophagectomy [28].
  • Formalin-fixed and paraffin-embedded tissue sections from esophageal biopsies and esophagectomy specimens with BM, with and without dysplasia and carcinoma, were immunostained for Fas and FasL using the immunoperoxidase technique [29].
  • METHODS: Twenty elective patients scheduled for thoracoabdominal esophagectomy under general anesthesia with propofol infusion were randomly allocated to receive either intravenous or epidural boluses of 50-100 micrograms fentanyl in a double-blind fashion to maintain hemodynamic stability [30].

Gene context of Esophagectomy

  • Depression of Th2-type cytokine production was more profound after transthoracic than after transhiatal esophagectomy (IL-4, P=.005; IL-13,P=.007) [31].
  • Surgical specimens from 75 patients with esophageal adenocarcinoma treated with esophagectomy were immunostained for endoglin, CD31, and VEGF [32].
  • Hence postoperative serum IL-6, IL-8, and HGF levels may be useful predictors of infection after esophagectomy [33].
  • METHODOLOGY: We studied p16, cyclin D1, and pRB expression using immunohistochemistry in the resected specimens of 156 patients who underwent curative esophagectomy [34].
  • We evaluated 126 patients who underwent esophagectomy in the National Taiwan University Hospital, and found that the status of p53 overexpression was significantly influenced by presence of codon 72 polymorphisms [35].

Analytical, diagnostic and therapeutic context of Esophagectomy


  1. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial. Schaefer, H., Engert, A., Grass, G., Mansmann, G., Wassmer, G., Hubel, K., Loehlein, D., Ulrich, B.C., Lippert, H., Knoefel, W.T., Hoelscher, A.H. Ann. Surg. (2004) [Pubmed]
  2. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Heitmiller, R.F., Redmond, M., Hamilton, S.R. Ann. Surg. (1996) [Pubmed]
  3. Resection margin for squamous cell carcinoma of the esophagus. Tsutsui, S., Kuwano, H., Watanabe, M., Kitamura, M., Sugimachi, K. Ann. Surg. (1995) [Pubmed]
  4. Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies. Algan, O., Coia, L.R., Keller, S.M., Engstrom, P.F., Weiner, L.M., Schultheiss, T.E., Hanks, G.E. Int. J. Radiat. Oncol. Biol. Phys. (1995) [Pubmed]
  5. Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy. Gabrielsen, T.O., Eldevik, O.P., Orringer, M.B., Marshall, B.L. AJNR. American journal of neuroradiology. (1995) [Pubmed]
  6. Gastropyloric motor activity and the effects of erythromycin given orally after esophagectomy. Nakabayashi, T., Mochiki, E., Garcia, M., Haga, N., Kato, H., Suzuki, T., Asao, T., Kuwano, H. Am. J. Surg. (2002) [Pubmed]
  7. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Vazquez-Sequeiros, E., Wang, L., Burgart, L., Harmsen, W., Zinsmeister, A., Allen, M., Jondal, M., Wiersema, M. Gastroenterology (2002) [Pubmed]
  8. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. Heath, E.I., Burtness, B.A., Heitmiller, R.F., Salem, R., Kleinberg, L., Knisely, J.P., Yang, S.C., Talamini, M.A., Kaufman, H.S., Canto, M.I., Topazian, M., Wu, T.T., Olukayode, K., Forastiere, A.A. J. Clin. Oncol. (2000) [Pubmed]
  9. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. Coia, L.R., Minsky, B.D., Berkey, B.A., John, M.J., Haller, D., Landry, J., Pisansky, T.M., Willett, C.G., Hoffman, J.P., Owen, J.B., Hanks, G.E. J. Clin. Oncol. (2000) [Pubmed]
  10. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ren, Y., Law, S., Huang, X., Lee, P.Y., Bacher, M., Srivastava, G., Wong, J. Ann. Surg. (2005) [Pubmed]
  11. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Xi, H., Baldus, S.E., Warnecke-Eberz, U., Brabender, J., Neiss, S., Metzger, R., Ling, F.C., Dienes, H.P., Bollschweiler, E., Moenig, S., Mueller, R.P., Hoelscher, A.H., Schneider, P.M. Clin. Cancer Res. (2005) [Pubmed]
  12. Transforming growth factor alpha expression as a potential survival prognosticator in patients with esophageal adenocarcinoma receiving high-dose radiation and chemotherapy. Sauter, E.R., Coia, L.R., Eisenberg, B.L., Hanks, G.E. Int. J. Radiat. Oncol. Biol. Phys. (1995) [Pubmed]
  13. Acid and duodenogastroesophageal reflux after esophagectomy with gastric tube reconstruction. Yuasa, N., Sasaki, E., Ikeyama, T., Miyake, H., Nimura, Y. Am. J. Gastroenterol. (2005) [Pubmed]
  14. Functioning of the intrathoracic stomach after esophagectomy. Nishikawa, M., Murakami, T., Tangoku, A., Hayashi, H., Adachi, J., Suzuki, T. Archives of surgery (Chicago, Ill. : 1960) (1994) [Pubmed]
  15. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus. Akgun, H., Lechago, J., Younes, M. Anticancer Res. (2002) [Pubmed]
  16. Comparison of initial distribution volume of glucose and intrathoracic blood volume during hemodynamically unstable States early after esophagectomy. Ishihara, H., Nakamura, H., Okawa, H., Yatsu, Y., Tsubo, T., Hirota, K. Chest (2005) [Pubmed]
  17. Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. Hübel, K., Mansmann, G., Schäfer, H., Oberhäuser, F., Diehl, V., Engert, A. Cytokine (2000) [Pubmed]
  18. Marked and prolonged depression of factor XIII after esophageal resection. Saito, H., Fukushima, R., Kobori, O., Kawano, N., Muto, T., Morioka, Y. Surgery today. (1992) [Pubmed]
  19. The effects of dopamine infusion on the postoperative energy expenditure, metabolism, and catecholamine levels of patients after esophagectomy. Nakagawa, M., Shinozawa, Y., Ando, N., Aikawa, N., Kitajima, M. Surgery today. (1994) [Pubmed]
  20. Why does sucralfate improve healing in reflux esophagitis? The role of sucrose octasulfate. Orlando, R.C., Tobey, N.A. Scand. J. Gastroenterol. Suppl. (1990) [Pubmed]
  21. Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer: evaluation by computed tomography and magnetic resonance imaging. Mizowaki, T., Nishimura, Y., Shimada, Y., Nakano, Y., Imamura, M., Konishi, J., Hiraoka, M. Int. J. Radiat. Oncol. Biol. Phys. (1996) [Pubmed]
  22. Perioperative treatment with filgrastim stimulates granulocyte function and reduces infectious complications after esophagectomy. Schäfer, H., Hübel, K., Bohlen, H., Mansmann, G., Hegener, K., Richarz, B., Oberhäuser, F., Wassmer, G., Hölscher, A.H., Pichlmaier, H., Diehl, V., Engert, A. Ann. Hematol. (2000) [Pubmed]
  23. Monoclonal origin of an esophageal carcinosarcoma producing granulocyte-colony stimulating factor: a case report. Ota, S., Kato, A., Kobayashi, H., Yonezumi, M., Yamaguchi, J., Musashi, M., Imamura, M., Asaka, M. Cancer (1998) [Pubmed]
  24. Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Sakamoto, K., Arakawa, H., Mita, S., Ishiko, T., Ikei, S., Egami, H., Hisano, S., Ogawa, M. Cytokine (1994) [Pubmed]
  25. Changes in immune function following surgery for esophageal carcinoma. Tashiro, T., Yamamori, H., Takagi, K., Hayashi, N., Furukawa, K., Nitta, H., Toyoda, Y., Sano, W., Itabashi, T., Nishiya, K., Hirano, J., Nakajima, N. Nutrition (Burbank, Los Angeles County, Calif.) (1999) [Pubmed]
  26. Metaplastic columnar mucosa in the cervical esophagus after esophagectomy. Oberg, S., Johansson, J., Wenner, J., Walther, B. Ann. Surg. (2002) [Pubmed]
  27. Clinical relevance of L-carnitine-supplemented total parenteral nutrition in postoperative trauma. Metabolic effects of continuous or acute carnitine administration with special reference to fat oxidation and nitrogen utilization. Pichard, C., Roulet, M., Schutz, Y., Rössle, C., Chiolero, R., Temler, E., Schindler, C., Zurlo, F., Fürst, P., Jéquier, E. Am. J. Clin. Nutr. (1989) [Pubmed]
  28. Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas. Horii, N., Nishimura, Y., Okuno, Y., Kanamori, S., Hiraoka, M., Shimada, Y., Imamura, M. Int. J. Radiat. Oncol. Biol. Phys. (2001) [Pubmed]
  29. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus. Younes, M., Lechago, J., Ertan, A., Finnie, D., Younes, A. Hum. Pathol. (2000) [Pubmed]
  30. Epidural and intravenous fentanyl produce equivalent effects during major surgery. Guinard, J.P., Carpenter, R.L., Chassot, P.G. Anesthesiology (1995) [Pubmed]
  31. Immune responses and prediction of major infection in patients undergoing transhiatal or transthoracic esophagectomy for cancer. van Sandick, J.W., Gisbertz, S.S., ten Berge, I.J., Boermeester, M.A., van der Pouw Kraan, T.C., Out, T.A., Obertop, H., van Lanschot, J.J. Ann. Surg. (2003) [Pubmed]
  32. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Saad, R.S., El-Gohary, Y., Memari, E., Liu, Y.L., Silverman, J.F. Hum. Pathol. (2005) [Pubmed]
  33. Serum interleukin-6, interleukin-8, hepatocyte growth factor, and nitric oxide changes during thoracic surgery. Yamada, T., Hisanaga, M., Nakajima, Y., Kanehiro, H., Watanabe, A., Ohyama, T., Nishio, K., Sho, M., Nagao, M., Harada, A., Matsushima, K., Nakano, H. World journal of surgery. (1998) [Pubmed]
  34. Concomitant analysis of p16/INK4, cyclin D1, and retinoblastoma protein expression in esophageal squamous cell carcinoma. Nakamura, T., Ide, H., Eguchi, R., Hayashi, K., Takasaki, K. Hepatogastroenterology (2003) [Pubmed]
  35. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Lee, J.M., Shun, C.T., Wu, M.T., Chen, Y.Y., Yang, S.Y., Hung, H.I., Chen, J.S., Hsu, H.H., Huang, P.M., Kuo, S.W., Lee, Y.C. Mutat. Res. (2006) [Pubmed]
  36. Pharmacokinetic assessment of an oligopeptide-based enteral formula in abdominal surgery patients. Ziegler, F., Nitenberg, G., Coudray-Lucas, C., Lasser, P., Giboudeau, J., Cynober, L. Am. J. Clin. Nutr. (1998) [Pubmed]
  37. Optimal treatment for localized esophageal cancer still uncertain. Lord, R.V. Am. J. Gastroenterol. (2000) [Pubmed]
  38. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Hironaka, S., Ohtsu, A., Boku, N., Muto, M., Nagashima, F., Saito, H., Yoshida, S., Nishimura, M., Haruno, M., Ishikura, S., Ogino, T., Yamamoto, S., Ochiai, A. Int. J. Radiat. Oncol. Biol. Phys. (2003) [Pubmed]
  39. Administration of epidural bupivacaine combined with epidural morphine after esophageal surgery. Terai, T., Yukioka, H., Fujimori, M. Surgery (1997) [Pubmed]
  40. Prostaglandin E1 ameliorates decreased tracheal blood flow after esophagectomy and aggressive upper mediastinal lymphadenectomy for esophageal carcinoma. Hasegawa, S., Imamura, M., Shimada, Y., Kanda, Y., Wada, H., Hitomi, S., Mori, K. J. Am. Coll. Surg. (1996) [Pubmed]
WikiGenes - Universities